<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31695223</PMID><DateCompleted><Year>2020</Year><Month>03</Month><Day>30</Day></DateCompleted><DateRevised><Year>2020</Year><Month>03</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0016-3813</ISSN><JournalIssue CitedMedium="Internet"><Volume>155</Volume><Issue>5</Issue><PubDate><Year>2019</Year></PubDate></JournalIssue><Title>Gaceta medica de Mexico</Title><ISOAbbreviation>Gac Med Mex</ISOAbbreviation></Journal><ArticleTitle>Aproximaci&#xf3;n gen&#xe9;tica en la esclerosis lateral amiotr&#xf3;fica.</ArticleTitle><Pagination><StartPage>513</StartPage><EndPage>521</EndPage><MedlinePgn>513-521</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.24875/GMM.19004927</ELocationID><Abstract><AbstractText>The superoxide dismutase type 1 (SOD1) gene is the first responsible gene mapped in amyotrophic lateral sclerosis type 1 (ALS1), and it codes for the enzyme SOD1, the function of which is to protect against damage mediated by free radicals deriving from oxygen. Its pathophysiological mechanism in ALS1 is related to ischemia. Several molecular studies of the SOD1 gene show that point mutations are the most frequent. The most common mutations in familial cases are p.A4V, p.I113Y, p.G37R, p.D90A and p.E100G, which account for more than 80% of cases, although intronic mutations have also been described as responsible for ALS1. Sporadic cases are explained by mutations in other genes such as SETX and C9orf72. ALS1 is a complex disease with genetic heterogeneity. On the other hand, familial and sporadic cases have a different etiology, which is explained by molecular heterogeneity and multiple pathogenic mechanisms that lead to ALS1; oxidative stress and ischemia are not the only cause. In Mexico, ALS molecular genetics studies are scarce. Clinical studies show an increase in cytokines such as adipsin in cerebrospinal fluid.</AbstractText><CopyrightInformation>Copyright: &#xa9; 2019 Permanyer.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cervantes-Arag&#xf3;n</LastName><ForeName>Iv&#xe1;n</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Universidad Guadalajara Lamar, Guadalajara, Jalisco. M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ram&#xed;rez-Garc&#xed;a</LastName><ForeName>Sergio Alberto</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Sistema de Universidades de Oaxaca, Instituto de Investigaciones Sobre la Salud P&#xfa;blica, Universidad de la Sierra Sur, Oaxaca. M&#xe9;xico.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Universidad de Colima, Facultad de Medicina, Colima. M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baltazar-Rodr&#xed;guez</LastName><ForeName>Luz Margarita</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>Universidad de Colima, Facultad de Medicina, Colima. M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garc&#xed;a-Cruz</LastName><ForeName>Diana</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Universidad de Guadalajara, Centro Universitario de Ciencias de la Salud, Departamento de Biolog&#xed;a Molecular y Gen&#xf3;mica, Jalisco. M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Casta&#xf1;eda-Cisneros</LastName><ForeName>Gema</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Instituto Mexicano del Seguro Social, Centro M&#xe9;dico Nacional de Occidente, Servicio de Neurocirug&#xed;a, Jalisco. M&#xe9;xico.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Mexico</Country><MedlineTA>Gac Med Mex</MedlineTA><NlmUniqueID>0010333</NlmUniqueID><ISSNLinking>0016-3813</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000073885">C9orf72 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064251">Multifunctional Enzymes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.1.-</RegistryNumber><NameOfSubstance UI="C484368">SETX protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.4.-</RegistryNumber><NameOfSubstance UI="D004265">DNA Helicases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.4.13</RegistryNumber><NameOfSubstance UI="D020365">RNA Helicases</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C531617">Amyotrophic lateral sclerosis 1</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073885" MajorTopicYN="N">C9orf72 Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004265" MajorTopicYN="N">DNA Helicases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007438" MajorTopicYN="N">Introns</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007511" MajorTopicYN="N">Ischemia</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064251" MajorTopicYN="N">Multifunctional Enzymes</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017354" MajorTopicYN="N">Point Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020365" MajorTopicYN="N">RNA Helicases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017382" MajorTopicYN="N">Reactive Oxygen Species</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="N">Superoxide Dismutase-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="spa"><AbstractText>El gen SOD1 es el primer gen responsable mapeado en la esclerosis lateral amiotr&#xf3;fica tipo 1 (ELA1) y codifica para la enzima super&#xf3;xido dismutasa tipo 1 (SOD1), cuya funci&#xf3;n es proteger del da&#xf1;o mediado de los radicales libres derivados del ox&#xed;geno; su mecanismo fisiopatol&#xf3;gico en ELA1 se relaciona con isquemia. Diversos estudios moleculares del gen SOD1 muestran que las mutaciones puntuales son las m&#xe1;s frecuentes. Las mutaciones m&#xe1;s comunes en los casos familiares son p.A4V, p.I113Y, p.G37R, p.D90A y p.E100G, que explican m&#xe1;s de 80 % de los casos, aunque tambi&#xe9;n se han descrito mutaciones intr&#xf3;nicas como responsables de esclerosis lateral amiotr&#xf3;fica tipo 1. Los casos espor&#xe1;dicos se explican por mutaciones en otros genes como SETX y C9orf72. ELA1 es una enfermedad compleja con heterogeneidad gen&#xe9;tica. Por otra parte, los casos familiares y espor&#xe1;dicos tienen etiolog&#xed;a distinta, lo cual se explica por la heterogeneidad molecular y m&#xfa;ltiples mecanismos patog&#xe9;nicos que conducen a ELA1; el estr&#xe9;s oxidativo y la isquemia no son la &#xfa;nica causa. En M&#xe9;xico son escasos los estudios de gen&#xe9;tica molecular de esclerosis lateral amiotr&#xf3;fica. Los estudios cl&#xed;nicos muestran incremento de citocinas como la adipsina en el l&#xed;quido cefalorraqu&#xed;deo.</AbstractText><CopyrightInformation>Copyright: &#xa9; 2019 Permanyer.</CopyrightInformation></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Atrofia muscular</Keyword><Keyword MajorTopicYN="N">Enfermedad de la neurona motora familiar</Keyword><Keyword MajorTopicYN="N">Familial motor neuron disease</Keyword><Keyword MajorTopicYN="N">Muscle atrophy</Keyword><Keyword MajorTopicYN="N">Superoxide dismutase 1</Keyword><Keyword MajorTopicYN="N">Super&#xf3;xido dismutasa 1</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>11</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>11</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>3</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31695223</ArticleId><ArticleId IdType="doi">10.24875/GMM.19004927</ArticleId><ArticleId IdType="pii">j155/5/513</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>